Asset Details
Do you wish to reserve the book?
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Do you wish to request the book?
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
2022
Overview
Nirmatrelvir is an M
pro
inhibitor active against SARS-CoV-2 and is given with ritonavir, a pharmacokinetic enhancer. In this double-blind, placebo-controlled trial, nirmatrelvir plus ritonavir, when given within 5 days after symptom onset to patients at high risk for disease progression, decreased the risk of Covid-19–related hospitalization or death by 87.8%.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antiviral Agents - administration & dosage
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ COVID-19
/ Diarrhea
/ Humans
/ Lactams - administration & dosage
/ Leucine - administration & dosage
/ Nitriles - administration & dosage
/ Original
/ Patients
/ Placebos
/ Proline - administration & dosage
/ Ritonavir - administration & dosage
/ Serology
/ Severe acute respiratory syndrome coronavirus 2
/ Viral Protease Inhibitors - administration & dosage
